Scarica l'app Stockscreener
25.13
0.76%
0.19
Dopo l'orario di chiusura:
25.09
-0.04
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks (NYSE:PFE) - Seeking Alpha
Pfizer (NYSE:PFE) Trading Down 0.2%Should You Sell? - MarketBeat
Amgen and Pfizer appoint new Science executives - European Pharmaceutical Review
Integrated Investment Consultants LLC Raises Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Pfizer Names New Head Of Research And Development - Baystreet.ca
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair - Zacks Investment Research
Mizuho Securities USA LLC Sells 69,459 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Is Pfizer Stock A Sell With Vaccine Skeptic Robert F. Kennedy Jr. Tapped To Lead HHS? - Yahoo! Voices
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist - The Motley Fool
Pfizer Inc. (NYSE:PFE) Shares Acquired by America First Investment Advisors LLC - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 4,546,809 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - Zacks Investment Research
Pfizer Inc. (NYSE:PFE) Shares Sold by Intech Investment Management LLC - MarketBeat
The Escalator: Pfizer, Eli Lilly, CVS Health and more - MM+M Online
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam) - BioSpace
Ontario Teachers Pension Plan Board Has $1.12 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief - GuruFocus.com
Pfizer elevates Chris Boshoff to top R&D role - pharmaphorum
Mitochondrial-Based Therapeutics Market Key Players Analysis - openPR
Zai Lab Partners with Pfizer to Commercialize Novel Antibiotic XACDURO in China | ZLAB Stock News - StockTitan
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia - Pharmaceutical Technology
PFIZER INC. (PFE) - MSN
Pfizer, Flynn Still Face Fines Over Epilepsy Drug Sale To NHS - Law360
Meta, Pfizer on DOL List of Upcoming Contractor Anti-Bias Audits - Bloomberg Law
Health Care Climbs as Obesity-Drug Makers ReboundHealth Care Roundup - Marketscreener.com
How Pfizer is trying to make U.S. healthcare easier to navigate - Fast Company
Pfizer Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pfizer Picks Boshoff To Head R&D, A Smooth Transition In An Uncertain Time - Citeline News & Insights
Pfizer (NYSE:PFE) Stock Price Down 0.6%Should You Sell? - MarketBeat
EC approval for Pfizer’s Hympavzi - The Pharma Letter
Pfizer promoted oncology chief Chris Boshoff to serve as CSO, R&D president - MM+M Online
Flagship reveals new agreements under Pfizer link-up - The Pharma Letter
Pzena Investment Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer, under pressure to change, names oncology head as new R&D chief - BioPharma Dive
Pfizer names oncology head Chris Boshoff as R&D chief - Reuters
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs - MSN
Pfizer Names New Chief Scientific Officer And President Of R&D - Contract Pharma
Company veteran named chief scientific officer at Pfizer - ShareCast
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO - BioSpace
Chris Boshoff takes on new role at Pfizer - The Pharma Letter
First Horizon Advisors Inc. Purchases 95,749 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer: Marketing authorization for Hympavzi in the EU - Marketscreener.com
Pfizer promotes oncology chief to lead R&D as activist Starboard circles - Financial Times
Pfizer: new Chief Scientific Officer on January 1 - Marketscreener.com
Pfizer bags EU okay for haemophilia drug Hympavzi - pharmaphorum
Pfizer names Chris Boshoff as new R&D chief starting 2025 - Investing.com
Pfizer names head of oncology as new R&D chief - Seeking Alpha
Pfizer names new chief scientific officer - baha news
Pfizer taps insider as chief science officer amid pressure from activist Starboard - MarketWatch
Pfizer Names New R&D Chief: Dr. Boshoff to Lead Scientific Innovation After 24 Drug Approvals | PFE Stock News - StockTitan
Flagship, Pfizer alliance yields two more startup deals - BioPharma Dive
Pfizer names Chris Boshoff as new R&D chief, WSJ reports - Marketscreener.com
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer - PR Newswire
Pfizer Names New R&D Chief - Yahoo! Voices
Is It Time to Sell Eli Lilly and Pfizer Stocks? - Yahoo! Voices
Pfizer's HYMPAVZI Wins EU Approval: First Weekly Treatment for Severe Hemophilia | PFE Stock News - StockTitan
StockNews.com Downgrades Pfizer (NYSE:PFE) to Buy - MarketBeat
Penicillin Drug Market: Comprehensive Analysis and Key Players-Pfizer, Inc., Novartis AG, Sanofi S.A - openPR
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight - BioSpace
Pfizer Unit Can't Get $75M Left In Insider Trading Deal Fund - Law360
Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules - Reuters
Pfizer loses bid to recoup $75 million left over from SEC settlement - Marketscreener.com
Depo Provera Lawsuit - Lawsuit Information Center Blog
Pfizer (NYSE:PFE) Trading Up 0.7%Here's What Happened - MarketBeat
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):